Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Philogen SpA ( (IT:PHIL) ) is now available.
Philogen S.p.A. has announced an update on its share buyback program, purchasing 902 shares between October 6 and October 10, 2025, at an average price of Euro 22.90 per share, totaling Euro 20,655.80. Since the program’s inception, Philogen has acquired 31,947 shares, representing 0.0787% of its share capital, with a total value of Euro 713,994.62. This strategic move is part of Philogen’s efforts to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (IT:PHIL) stock is a Hold with a EUR24.50 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating high-mortality diseases. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers through advanced technologies. Philogen’s main therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumor masses while sparing healthy tissues. The company aims to generate and commercialize innovative treatments for diseases lacking satisfactory therapies, leveraging proprietary technologies, extensive experience, and a broad portfolio of patents.
YTD Price Performance: 17.44%
Average Trading Volume: 15,211
Technical Sentiment Signal: Buy
Current Market Cap: €669.7M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.